ERBB2 and breast carcinoma: In order to corroborate previous reports that dinaciclib-induced MCL-1 decreases are due to loss of MCL-1 transcription10, we evaluated MCL-1 mRNA expression after treating different HER2-amplified breast cancer cell lines with dinaciclib (Fig. 1B).